Holoxan (Ifosfamide)
Alkylating chemotherapy agent for cancer treatment
Quick facts about Holoxan (Ifosfamide)
Key Takeaways About Holoxan
- Hospital-only medication: Holoxan is always administered intravenously by healthcare professionals in a hospital or clinic setting
- Bladder protection is essential: Mesna (Uromitexan) must always be given alongside Holoxan to prevent hemorrhagic cystitis (bladder inflammation and bleeding)
- Regular blood monitoring required: Blood counts must be checked before and during each treatment cycle, as Holoxan significantly affects bone marrow function
- Neurotoxicity risk: 10-20% of patients may develop encephalopathy (brain dysfunction); report confusion, drowsiness, or hallucinations immediately
- Fertility may be affected: Discuss sperm or egg freezing with your doctor before starting treatment; use effective contraception during and for 6 months after treatment
What Is Holoxan and What Is It Used For?
Holoxan (ifosfamide) is an alkylating chemotherapy agent that damages the DNA of cancer cells, preventing their growth and division. It is used to treat a wide range of cancers including soft tissue sarcomas, testicular cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer, ovarian cancer, and various pediatric malignancies.
Ifosfamide belongs to the class of alkylating agents known as nitrogen mustard analogs. It is a synthetic chemical compound that was first developed in the 1960s and has since become a cornerstone of many cancer treatment regimens worldwide. The World Health Organization (WHO) includes ifosfamide on its Model List of Essential Medicines, recognizing its critical importance in oncology.
As a prodrug, ifosfamide must be activated by enzymes in the liver (specifically the cytochrome P450 system) before it becomes pharmacologically active. Once activated, the drug's metabolites form cross-links between and within DNA strands of cancer cells. These cross-links prevent the DNA from being properly replicated during cell division, ultimately leading to cancer cell death. This mechanism makes ifosfamide effective against rapidly dividing cancer cells, although it can also affect normal cells, leading to its characteristic side effect profile.
Holoxan is used in the treatment of many different cancer types. The specific cancers for which it is commonly prescribed include soft tissue sarcomas (including rhabdomyosarcoma), bone sarcomas such as Ewing sarcoma and osteosarcoma, testicular germ cell tumors, non-Hodgkin lymphoma, Hodgkin lymphoma, small cell and non-small cell lung cancer, bladder cancer, ovarian cancer, cervical cancer, breast cancer, and Wilms tumor in children. In most cases, ifosfamide is given as part of a combination chemotherapy regimen rather than as a single agent.
Holoxan is always administered in a hospital or specialized cancer treatment center. It is never taken at home. Your oncologist will determine the appropriate treatment regimen based on your specific cancer type, disease stage, and overall health. Holoxan is typically given as part of a multi-drug chemotherapy protocol.
How does Holoxan work in the body?
After intravenous administration, ifosfamide is transported to the liver where it undergoes enzymatic activation by cytochrome P450 enzymes (primarily CYP3A4 and CYP2B6). This activation produces several metabolites, including the cytotoxic isophosphoramide mustard and the uroprotective metabolite acrolein. Isophosphoramide mustard alkylates DNA by forming covalent bonds with the nucleotide bases, creating both interstrand and intrastrand cross-links. These cross-links interfere with DNA replication, transcription, and repair mechanisms, triggering apoptosis (programmed cell death) in the affected cancer cells.
Unfortunately, acrolein is toxic to the bladder lining (urothelium), which is why mesna (Uromitexan) is routinely co-administered. Mesna binds to acrolein in the urinary tract, forming a non-toxic compound that is safely excreted. The half-life of ifosfamide varies depending on the dose, typically ranging from 4 to 7 hours at standard doses and up to 15 hours at higher doses.
What Should You Know Before Taking Holoxan?
Holoxan must not be used in patients with severe bone marrow suppression, active urinary tract infections or bladder obstruction, severe kidney impairment, active infections, brain metastases, known hypersensitivity to ifosfamide, or during breastfeeding. Several precautions apply for patients with diabetes, heart disease, or impaired organ function.
Before starting treatment with Holoxan, your oncologist will conduct a thorough evaluation of your overall health, including blood tests to assess your bone marrow function, kidney function, and liver function. This assessment is essential to determine whether Holoxan is safe for you and to establish the correct dosage. It is critical that you inform your doctor about all existing medical conditions, current medications, and any previous cancer treatments you have received.
Contraindications
You must not receive Holoxan in the following situations:
- Hypersensitivity to ifosfamide: If you have previously had an allergic reaction to ifosfamide, including symptoms such as difficulty breathing, wheezing, itching, or swelling of the face and lips
- Severe bone marrow suppression: Particularly if you have received extensive prior chemotherapy and/or radiation therapy. Blood tests will be performed to verify adequate bone marrow function
- Severe kidney impairment: If your kidneys are not functioning adequately, or if you have urinary tract obstruction or active urinary tract infection (cystitis), which may present as pain or burning during urination
- Active infections: Holoxan suppresses the immune system and must not be given during ongoing infections
- Brain metastases: The presence of secondary tumors in the brain is a contraindication for ifosfamide treatment
- Breastfeeding: Ifosfamide passes into breast milk and breastfeeding must be discontinued during treatment
Warnings and Precautions
Talk to your doctor before receiving Holoxan if any of the following apply to you:
- You notice blood in your urine – contact your doctor immediately as this may indicate bladder damage
- You have diabetes – ifosfamide can affect blood sugar levels
- You have recently undergone or are currently receiving radiation therapy or other chemotherapy
- You have heart problems or have received radiation to the chest area
- You have impaired kidney function, liver function, or pre-existing bone marrow damage
- You are planning to become pregnant – see the section on pregnancy and fertility below
- You have received or are receiving cisplatin before or during ifosfamide treatment
Holoxan can affect brain function (encephalopathy) in 10-20% of treated patients. Symptoms typically appear within hours to days after starting treatment and may include abnormal drowsiness, severe headache, confusion, altered perception of reality, hallucinations, seizures, blurred vision, and loss of bladder control. Report any of these symptoms to your medical team immediately. Encephalopathy is usually reversible when treatment is stopped and appropriate supportive care is provided.
Effects on the blood and immune system
Holoxan significantly affects blood cell production in the bone marrow. Blood cells are produced in the bone marrow and include three main types: red blood cells (which carry oxygen), white blood cells (which fight infections), and platelets (which help blood to clot). After receiving Holoxan, the number of all three types of blood cells will decrease. This is an unavoidable effect of the medication.
Blood cell counts typically reach their lowest point approximately 8-10 days after beginning treatment and remain low for several days after the treatment cycle is completed. Most patients recover normal blood cell levels within 21-28 days. If you have received extensive prior chemotherapy, recovery may take longer. During the period when your blood counts are low, you are at increased risk of infections. Try to avoid close contact with people who have coughs, colds, or other infections. Your medical team will monitor your blood counts before and during treatment.
Effects on the bladder
One of the characteristic toxicities of ifosfamide is damage to the bladder lining (urothelium), which can cause hemorrhagic cystitis – inflammation of the bladder with bleeding. This occurs because acrolein, a toxic metabolite of ifosfamide, is concentrated in the urine. To prevent this complication, your doctor will prescribe mesna (Uromitexan), a uroprotective agent that neutralizes acrolein in the urinary tract.
Mesna can be administered as an intravenous injection, mixed with the ifosfamide infusion, or taken as tablets. Most patients who receive Holoxan together with mesna do not experience bladder problems. However, your medical team may test your urine for blood content using a dipstick test or microscopy as a precautionary measure. Adequate hydration during treatment is also important for bladder protection.
Effects on the kidneys
Holoxan can damage the kidneys, impairing their function. This risk is higher if you have only one kidney or if your kidneys are already compromised. Kidney damage is often temporary and kidney function typically returns to normal once ifosfamide treatment is stopped. However, in some cases, the damage may be more permanent and severe, particularly in children or patients receiving high cumulative doses. Your doctor will regularly monitor kidney function through blood tests and urine analysis throughout treatment.
Effects on the heart
Ifosfamide can damage the heart or affect its rhythm (cardiotoxicity). The risk of cardiac complications increases with higher doses of ifosfamide, concurrent radiation therapy, treatment with other cardiotoxic chemotherapy agents (such as anthracyclines), and in older patients. Your doctor may perform heart function tests (such as echocardiography or ECG) before and during treatment to monitor for any cardiac effects.
Effects on the liver
Holoxan can have potentially life-threatening effects on the liver. If you experience sudden weight gain, pain in the liver area (upper right abdomen), or jaundice (yellowing of the skin or eyes), inform your medical team immediately. Liver function tests will be performed regularly during treatment.
Effects on the lungs
Ifosfamide can cause inflammation or scarring (fibrosis) of the lungs. Pulmonary complications may develop more than six months after treatment. If you experience difficulty breathing or persistent cough, report this to your doctor promptly.
Pregnancy and Breastfeeding
You must not become pregnant while receiving Holoxan, as it can cause miscarriage or harm the developing fetus. Inform your doctor immediately if you are pregnant, suspect you may be pregnant, or are planning to become pregnant. Neither men nor women should attempt to conceive a child during treatment or for at least 6 months after the last dose. Effective contraception must be used during this period. Consult your doctor for guidance on appropriate contraceptive methods.
Holoxan can affect your ability to have children (fertility). Discuss the possibility of sperm banking (for men) or egg freezing (for women) with your doctor before starting treatment. Ifosfamide passes into breast milk, and breastfeeding must be discontinued during treatment.
Driving and operating machinery
Certain side effects of Holoxan – including seizures, involuntary movements, dizziness, blurred vision, visual impairment, nausea, and vomiting – may impair your ability to react and concentrate. You should therefore avoid driving or operating machinery until you know how you react to Holoxan. Discuss with your medical team when it is safe to resume these activities.
How Does Holoxan Interact with Other Drugs?
Holoxan interacts with many medications including diabetes drugs, blood thinners (warfarin), certain antibiotics, antifungals, anti-epileptics, and other chemotherapy agents. Always inform your medical team about all medications you are taking. Live vaccines must be avoided during ifosfamide treatment.
When Holoxan is used together with other medications, its effects may be altered, or the effects of the other medications may change, which can increase the risk of side effects and other unwanted effects. It is crucial that you inform your doctor about all medications you are currently taking, have recently taken, or may take, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins.
Major Interactions
| Drug/Class | Interaction | Clinical Significance |
|---|---|---|
| Cisplatin, Carboplatin | Increased nephrotoxicity and ototoxicity; altered ifosfamide metabolism | Requires close monitoring of kidney function and hearing |
| Warfarin | Holoxan may increase the anticoagulant effect | Frequent INR monitoring required; dose adjustment likely needed |
| Phenytoin, Carbamazepine, Phenobarbital | These anti-epileptics induce CYP3A4, increasing ifosfamide activation and toxicity | Increased risk of neurotoxicity and other adverse effects |
| Ketoconazole, Fluconazole, Itraconazole | CYP3A4 inhibitors that may alter ifosfamide metabolism | May reduce activation or alter toxicity profile |
| Rifampicin | Strong CYP3A4 inducer that significantly increases ifosfamide activation | Substantially increased risk of toxicity; combination requires caution |
| Anthracyclines (Doxorubicin) | Additive cardiotoxicity | Increased risk of heart damage; cardiac monitoring essential |
| Aminoglycosides, Amphotericin B | Additive nephrotoxicity | Enhanced kidney damage risk; renal monitoring required |
Minor Interactions
| Drug/Class | Interaction | Clinical Significance |
|---|---|---|
| Sulfonylureas (glibenclamide, glipizide, glimepiride) | Holoxan may enhance the blood sugar-lowering effect | Monitor blood glucose more frequently |
| Tamoxifen | Possible increased risk of thromboembolic events | Monitor for signs of blood clots |
| ACE Inhibitors, Hydrochlorothiazide | Potential alteration of ifosfamide metabolism or toxicity | Be aware of potential changes in blood pressure control |
| Allopurinol | May increase myelosuppressive effects of ifosfamide | More frequent blood count monitoring |
| Succinylcholine (Suxamethonium) | Ifosfamide can prolong the effect of this muscle relaxant | Inform your anesthetist if surgery is planned |
| St. John's Wort (Hypericum) | CYP3A4 inducer that may alter ifosfamide activation | Avoid during ifosfamide treatment |
Because Holoxan suppresses the immune system, live vaccines must be avoided during treatment, as they could cause an infection. Additionally, the effectiveness of any vaccination may be reduced during ifosfamide therapy. Always consult your oncologist before receiving any vaccinations.
Alcohol: Consuming alcohol while receiving ifosfamide may increase the risk of nausea and vomiting. Discuss alcohol consumption with your medical team.
CNS-active medications: If you develop signs of encephalopathy (brain dysfunction), medications that affect the central nervous system – including anti-nausea medications, sedatives, opioid painkillers, and antihistamines – should be used with extreme caution or discontinued. Inform your medical team about all such medications.
What Is the Correct Dosage of Holoxan?
Holoxan dosage is determined individually by your oncologist based on your cancer type, body surface area, overall health, and concurrent treatments. It is administered as an intravenous infusion in hospital, typically given in treatment cycles with rest periods between courses. Dosage typically ranges from 1.2 to 2.4 g/m²/day for 3-5 consecutive days per cycle.
Holoxan is always prepared and administered by trained healthcare professionals in a hospital or specialized cancer treatment center. The powder is dissolved in water for injection and then diluted further in an infusion solution for intravenous administration. The infusion is typically given over several hours, and in some regimens, may be administered continuously over several days. The exact dosing schedule depends on your specific cancer type and the treatment protocol being followed.
Standard Adult Dosing
Typical Adult Dose Ranges
The dose of ifosfamide varies widely depending on the treatment regimen. Common dosing approaches include:
- Fractionated dosing: 1.2 to 2.4 g/m²/day for 3 to 5 consecutive days, repeated every 3 to 4 weeks
- High-dose regimens: Up to 5 g/m² as a single dose or divided over 24 hours (used in specific protocols, typically with enhanced supportive care)
- Continuous infusion: For 24-hour infusions, ifosfamide is typically diluted in approximately 3 liters of sodium chloride or glucose infusion solution
The maximum concentration for direct intravenous injection is 40 mg/ml. All dosing decisions are made by your oncologist based on your individual clinical circumstances.
Factors Affecting Dosage
Several factors influence how your oncologist determines the appropriate dose:
- Type of cancer: Different cancers require different dosing protocols
- Body surface area: Calculated from your height and weight; dosing is expressed as grams per square meter (g/m²)
- General health status: Kidney function, liver function, and bone marrow reserve all affect dose selection
- Prior and concurrent treatments: Previous chemotherapy, radiation therapy, or concurrent medications may necessitate dose modifications
- Blood counts: Adequate white blood cell and platelet counts are required before each cycle
Treatment Cycles
Holoxan is typically given as a series of treatment cycles (courses). After each treatment cycle, there is a rest period (a period without ifosfamide administration) to allow your body – particularly your bone marrow – to recover before the next cycle begins. The number of treatment cycles and the duration of rest periods depend on your treatment protocol and how you respond to therapy.
Dose Adjustments
Your doctor may need to adjust your dose based on how you tolerate the treatment. Dose reductions or treatment delays may be necessary in the following situations:
- Low white blood cell count (neutropenia) or low platelet count (thrombocytopenia)
- Deteriorating kidney function
- Signs of neurotoxicity (encephalopathy)
- Liver function abnormalities
- Significant cardiac side effects
Overdose
Since Holoxan is administered by healthcare professionals in a controlled hospital setting, overdose is extremely unlikely. If an overdose were to occur, the infusion would be stopped immediately. There is no specific antidote for ifosfamide. Management of overdose would be supportive, with close monitoring and treatment of any symptoms that develop. In the event of suspected overdose, contact your medical team or emergency services immediately.
What Are the Side Effects of Holoxan?
Holoxan can cause a wide range of side effects. The most common (affecting more than 1 in 10 patients) include bone marrow suppression, nausea and vomiting, hair loss, neurotoxicity including encephalopathy (10-20% of patients), hemorrhagic cystitis, and fever. Always report unusual symptoms to your medical team immediately.
Like all chemotherapy medications, Holoxan can cause side effects, although not every patient will experience them. Some side effects are common and expected, while others are rare but potentially serious. Your medical team is experienced in managing these side effects and will monitor you closely during treatment. It is important to report any new or worsening symptoms promptly.
- Swelling of the face, tongue, or throat; difficulty swallowing; hives or difficulty breathing (angioedema)
- Confusion, severe drowsiness, loss of consciousness, hallucinations, blurred vision, seizures (encephalopathy)
- Extensive skin rash, itching, facial swelling, difficulty breathing (severe allergic reaction)
- Difficulty breathing and/or pain when breathing in (possible lung inflammation)
- Unexplained muscle pain, cramps, or weakness
Very Common
- Bone marrow suppression (low white blood cells, low platelets, anemia)
- Nausea and vomiting
- Hair loss (alopecia)
- Neurotoxicity affecting the central nervous system
- Encephalopathy (brain dysfunction) – occurs in 10-20% of patients within hours to days of treatment start
- Hemorrhagic cystitis (bladder inflammation with bleeding)
- Fever
Common
- Infections
- Metabolic acidosis (decreased blood pH)
- Decreased appetite
- Phlebitis (inflammation of blood vessels at injection site)
- Liver toxicity leading to impaired liver function or acute hepatitis
- Absence or reduction of sperm in semen
- Fatigue, malaise, general physical deterioration
Uncommon
- Sepsis (blood poisoning) and septic shock
- Treatment-related secondary cancers (leukemia, sarcoma, lymphoma, myelodysplastic syndrome)
- Altered mental state including mania, paranoia, delirium, panic attacks
- Dizziness
- Cardiac toxicity, arrhythmias, heart failure, low blood pressure
- Diarrhea, constipation, mouth inflammation (stomatitis)
- Elevated liver enzymes
- Bladder irritation, urinary incontinence
- Disrupted ovulation, absence of menstruation
Rare
- Muscle cramps
- Skin and mucous membrane inflammation
- Various types of skin rash
- Hypersensitivity reactions
- Kidney disease, acute or chronic kidney failure
- Abnormal urine analysis (proteinuria, phosphaturia, aminoaciduria)
- SIADH with low blood sodium, dehydration, fluid retention
- Electrolyte imbalances
- Shortness of breath (dyspnea), cough
- Blurred vision
- Local reactions at injection/infusion site
Very Rare
- Severe coagulation disorders
- Hemolytic uremic syndrome (HUS)
- Severe anaphylactic reaction
- Polyneuropathy (nerve disease)
- Seizures including epilepsy
- Cardiac arrest, myocardial infarction
- Fanconi syndrome (kidney tubular disorder)
- Visual impairment
- Pulmonary edema, pulmonary fibrosis, interstitial pneumonitis
- Acute pancreatitis
- Toxic epidermal necrolysis (severe skin reaction with skin detachment)
After completing treatment with Holoxan, ovulation (in women who have not entered menopause) and sperm production in men usually return to normal. However, in some cases, ovulation or sperm production may not normalize, which can result in permanent infertility. Discuss fertility preservation options with your doctor before starting treatment.
How Should You Store Holoxan?
Holoxan should be stored below 25°C (77°F) and kept out of the sight and reach of children. The reconstituted solution must be used within 12 hours. Do not use after the expiration date printed on the carton and vial.
As Holoxan is a hospital-administered medication, storage is handled by the hospital pharmacy. However, for reference, the following storage conditions apply:
- Temperature: Store below 25°C (77°F)
- Keep out of the sight and reach of children
- Expiration: Do not use after the expiration date (EXP) stated on the carton and vial. The expiration date refers to the last day of that month
- Reconstituted solution: Must be used within 12 hours of preparation
Holoxan is a cytotoxic (cell-damaging) substance. Hospital pharmacies follow strict protocols for the handling, preparation, and disposal of cytotoxic agents. The powder is reconstituted in a dedicated preparation area (ideally a laminar flow cabinet) by trained staff wearing protective equipment including gloves, gowns, and eye protection. Any unused product or waste material must be disposed of in accordance with local regulations for cytotoxic waste.
What Does Holoxan Contain?
Each vial of Holoxan contains ifosfamide as the sole active ingredient, available in strengths of 500 mg, 1000 mg, or 2000 mg. The product contains no excipients (inactive ingredients). It appears as a white or almost white crystalline powder in a glass injection vial.
Holoxan is a single-ingredient formulation, meaning it contains only the active substance ifosfamide with no additional excipients or inactive ingredients. This simplicity of formulation reduces the risk of excipient-related adverse reactions.
Product description
- Active substance: Ifosfamide
- Available strengths: 500 mg, 1000 mg, or 2000 mg per injection vial
- Inactive ingredients: None
- Appearance: White or almost white crystalline powder
- Packaging: Glass injection vial sealed with a bromobutyl rubber stopper and aluminum/plastic cap, packaged individually
- Protective packaging: Some vials are packaged with an additional protective plastic casing consisting of a transparent cylindrical polypropylene container with a blue polyethylene screw cap, providing extra transport safety for medical and pharmaceutical personnel
Preparation of the solution
Holoxan powder is dissolved in water for injection (not in normal saline). The reconstitution process involves adding water slowly along the side of the vial to prevent the powder from swirling up. The dissolution must not be accelerated by heating. For intravenous injection, the maximum concentration is 40 mg/ml (25 ml of water for injection per 1000 mg of Holoxan). For intravenous infusion, the reconstituted solution is further diluted with sodium chloride, glucose, or fructose infusion solutions. Mesna may be added to the same infusion bag.
Frequently Asked Questions About Holoxan
Medical References & Sources
All medical information on this page is based on peer-reviewed research and international medical guidelines. The following sources have been used:
- European Medicines Agency (EMA). Summary of Product Characteristics: Ifosfamide. European public assessment reports. Available at: ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization. Available at: who.int
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Various tumor-specific guidelines. Available at: nccn.org
- British National Formulary (BNF). Ifosfamide Monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001;40(1):41-62. doi:10.2165/00003088-200140010-00004
- Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy. Clin Pharmacol Ther. 2000;68(6):597-604. doi:10.1067/mcp.2000.111539
- Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991;42(3):428-467. doi:10.2165/00003495-199142030-00006
- Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003;41(3):190-197. doi:10.1002/mpo.10336
This article follows the GRADE evidence framework. Evidence levels range from 1A (highest quality: systematic reviews of randomized controlled trials) to 4 (expert opinion). The pharmacological and safety information presented here is based primarily on Level 1A-2B evidence from regulatory authority assessments, systematic reviews, and well-conducted clinical trials.
About Our Medical Editorial Team
This article has been written and reviewed by our medical editorial team, which consists of specialist physicians in oncology, clinical pharmacology, and internal medicine with documented academic background and clinical experience in cancer treatment.
📋 Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
🔍 Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
🔄 Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
✎ Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in oncology, clinical pharmacology, hematology, and internal medicine.